10:42 AM EST - HLS Therapeutics Inc. : Announced its financial results for the three-month periods ended September 30, 2019. All amounts are in United States dollars. Revenue was $13.4 million compared to $15.3 million in Q3 2018. Adjusted EBITDA was $8.0 million compared to $10.3 million in Q3 2018. Net loss was ($2.0) million, or ($0.06) per common share, compared to net loss of ($19.7) million, or ($0.72) per common share, in Q3 2018. HLS Therapeutics Inc.
shares T.HLS are trading up $0.03 at $15.03.
